Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis

Journal of Clinical and Experimental Hepatology

Volumn 8, Issue 1, 2018, Pages 15-22

  Abdel Aziz, Asmaa M ^a   Ibrahim, Mohamed A ^a   El Sheikh, Azza A ^a,b   Kamel, Maha Y ^a   Zenhom, Nagwa M ^a   Abdel Raheim, Salam ^a   Abdelhaleem, Hisham ^a  

^a Minia University   (Egypt)

^b PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

Author keywords

daclatasvir; HCV; IL 18 polymorphism; sofosbuvir

Indexed keywords

ALBUMIN; BILIRUBIN; DACLATASVIR; HEMOGLOBIN; INTERLEUKIN 18; PEGINTERFERON ALPHA; RIBAVIRIN; SOFOSBUVIR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERBILIRUBINEMIA; INSOMNIA; INTERLEUKIN 18 GENE; INTERNATIONAL NORMALIZED RATIO; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PLATELET COUNT; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIREMIA;

EID: 85022011317     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2017.06.006     Document Type: Article

References (31)

1. Parfieniuk, A., Jaroszewicz, J., Flisiak, R., Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol 21 (2007), 5673–5681.
2. Breban, R., Doss, W., Esmat, G., et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 20 (2013), 294–296.
3. Abdel-Aty, M., Fouad, M., Sallam, M.M., et al. Incidence of HCV induced-esophageal varices in Egypt: valuable knowledge using data mining analysis. Medicine (Baltimore), 96, 2017, e5647 doi:10.1097.
4. Asselah, T., Marcellin, P., Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 32:suppl 1 (2012), 88–102.
5. Koff, R.S., The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 39 (2014), 478–487.
6. Kirby, B.J., Symonds, W.T., Kearney, B.P., Mathias, A.A., Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 54 (2015), 677–690.
7. Bernuth, S., Yagmur, E., Schuppan, D., et al. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis 48 (2016), 291–297.
8. Fontana, R.J., Brown, R.S., Moreno-Zamora, A., et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl 22 (2016), 446–458.
9. Asselah, T., Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol 61 (2014), 435–438.
10. Sulkowski, M., Gardiner, D., Rodriguez-Torres, M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 16 (2014), 211–221.
11. Kamal, S.M., Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepatic Med 6 (2014), 61–77.
12. Santos, K.N., Almeida, M.K., Fecury, A.A., Costa, C.A., Martins, L.C., Analysis of polymorphism in the interleukin 18 gene promotor (-137 G/C and -607 C/A) in patients infected with hepatitis c virus from the Brazilian Amazon. Arq Gastroenterol 52 (2015), 222–227.
13. Sterling, R.K., Lissen, E., Clumeck, N., et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 43 (2005), 1317–1325.
14. Zhang, Y.F., Shi, H., Chen, L.B., Xu, Q.H., Value of FIB-4 for the diagnosis of liver fibrosis in chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue ZaZhi 24 (2010), 215–217.
15. European Association for Study of Liver, EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
16. Medrano, J.F., Aasen, E., Sharrow, L., DNA extraction from nucleated red blood cells. Biotechniques, 8, 1990, 43.
17. An, P., Thio, C.L., Kirk, G.D., Donfield, S., Goedert, J.J., Winkler, C.A., Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance. J Infect Dis 198 (2008), 1159–1165.
18. Hezode, C., Alric, L., Brown, A., et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (command-4). Antivir Ther 21 (2015), 195–205.
19. Murakami, E., Imamura, M., Hayes, C.N., et al. Ultra deep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother 58 (2014), 2105–2112.
20. Stedman, C., Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 7 (2014), 131–140.
21. Poordad, F., Schiff, E.R., Vierling, J.M., et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 63 (2016), 1493–1505.
22. Afdhal, N., Zeuzem, S., Kwo, P., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370 (2014), 1889–1898.
23. Guarino, M., Morisco, F., Valvano, M.R., et al. Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis. Aliment Pharmacol Ther 45:9 (2017), 1193–1200.
24. Wu, L.S., Jimmerson, L.C., MacBrayne, C.E., Kiser, J.J., D'Argenio, D.Z., Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus. CPT Pharmacometr Syst Pharmacol 5 (2016), 65–73.
25. Dyson, J.K., Hutchinson, J., Harrison, L., et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 64 (2016), 234–238.
26. Lee, C., Daclatasvir potential role in hepatitis C. Drug Des Dev Ther 7 (2013), 1223–1233.
27. University of Liverpool Hepatitis Drug Interactions. Website: https://www.liverpool.ac.uk/www.hep_druginteractions.org. Accessed October 2016.
28. Soriano, V., Labarga, P., Barreiro, P., et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 11 (2015), 333–341.
29. Haas, S.L., Weiss, C., Bugert, P., et al. Interleukin 18 promoter variants (-137G>C and -607C>A) in patients with chronic hepatitis C: association with treatment response. J Clin Immunol 29 (2009), 620–628.
30. Yang, Y., Liu, H., Association between interleukin-18 gene promoter (−607C/A and −137G/C) polymorphisms and chronic hepatitis C virus infections: a meta-analysis. Meta Gene 5 (2015), 21–31.
31. Abdelraheem, W.M., Hassuna, N.A., Abuloyoun, S.M., Abdel Ghany, H.M., Rizk, H.A., Abdelwahab, S.F., Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin. Arch Virol 161 (2016), 2473–2480.